TauTaTis: Tau now

Building on years of incremental progress in research on small molecule kinase inhibition for CNS disorders, TauTaTis Inc. was formed last year to develop a preclinical program designed to address the underlying pathologies of neurodegenerative conditions including Alzheimer's and Parkinson's diseases.

The company's TTT-3002 is a small molecule that inhibits a pair of undisclosed kinase families associated with the MAP kinase pathway. TauTaTis believes the compound blocks the aberrant hyperphosphorylation of tau, a process thought to play a key role in neuronal degeneration...